FSA Advisors Inc. Makes New $1.19 Million Investment in Merck & Co., Inc. $MRK

FSA Advisors Inc. purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,280 shares of the company’s stock, valued at approximately $1,187,000.

A number of other hedge funds have also recently added to or reduced their stakes in MRK. Barnes Dennig Private Wealth Management LLC boosted its stake in Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after buying an additional 266 shares during the last quarter. United Financial Planning Group LLC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter worth about $31,000. Wealth Watch Advisors INC purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter worth about $34,000. Dunhill Financial LLC raised its holdings in shares of Merck & Co., Inc. by 83.0% in the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock worth $35,000 after purchasing an additional 190 shares during the period. Finally, Silicon Valley Capital Partners raised its holdings in shares of Merck & Co., Inc. by 160.5% in the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock worth $35,000 after purchasing an additional 260 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. TD Cowen raised their price objective on Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a report on Tuesday, January 20th. Barclays assumed coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective on the stock. Cantor Fitzgerald raised their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Guggenheim raised their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $112.30 on Monday. The stock’s 50-day moving average is $117.69 and its 200-day moving average is $107.70. The company has a market cap of $277.36 billion, a price-to-earnings ratio of 31.63, a price-to-earnings-growth ratio of 2.27 and a beta of 0.18. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 26.84% and a net margin of 13.59%.The company’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 4.9 earnings per share for the current year.

Insider Buying and Selling at Merck & Co., Inc.

In related news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the sale, the insider directly owned 21,197 shares in the company, valued at approximately $2,583,278.39. This trade represents a 41.44% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares in the company, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 320,176 shares of company stock worth $38,281,735. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
• Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2‑drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long‑term growth optionality. Merck expands beyond oncology
• Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
• Neutral Sentiment: FY‑2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
• Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck‑specific news. Moderna Covid vaccine drives growth
• Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.